arrow
X

Xiequn Chen

northwest university xi'an
H指数:25
被引数:2,265

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Discrepancies in Treatment Goals and Concerns Regarding Disease Management between Patients with Myeloproliferative Neoplasms and Hematologists in China: Analysis from a Multicenter Cross-Sectional Survey
2025-10-010
PRE
Aponermin or placebo in combination with thalidomide and dexamethasone in the treatment of relapsed or refractory multiple myeloma (CPT-MM301): a randomised, double-blinded, placebo-controlled, phase 3 trial

Aponermin或安慰剂联合沙利度胺和地塞米松治疗复发或难治性多发性骨髓瘤 (CPT-MM301): 一项随机,双盲,安慰剂对照的3期试验

2023-10-1413
OAAI
A life-threatening bleeding prediction model for immune thrombocytopenia based on personalized machine learning: a nationwide prospective cohort study

基于个性化机器学习的免疫性血小板减少症危及生命的出血预测模型: 一项全国性前瞻性队列研究

2023-09-016
OAAI
Expert consensus on microtransplant for acute myeloid leukemia in elderly patients -report from the international microtransplant interest group
HELIYON
IF3.6
2023-04-017
OAAI
2021 Chinese consensus on the diagnosis and management of primary immune thrombocytopenia in pregnancy
2022-04-206
OAAI
Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study
2022-04-0519
OAAI
Anthracycline dose optimisation in patients with diffuse large B-cell lymphoma: a multicentre, phase 3, randomised, controlled trial
2019-06-0133
PREAI
Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study

艾扎佐米联合来那度胺-地塞米松治疗复发/难治性多发性骨髓瘤的随机、双盲、安慰剂对照III期临床研究: 中国延续研究

2017-07-0670
OAAI
Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China
2017-03-15200
OAAI
Genomic Profiling of Adult and Pediatric B-cell Acute Lymphoblastic Leukemia
2016-06-01254
OAAI